In the first step, BDC-1001 enters the body using a trastuzumab analog that specifically binds to HER2-expressing tumor cells and kills them. The second step involves activating innate immunity. When binding to tumor cells, the Fc segment of the IgG1 antibody binds to the Fc receptor (Fcγ...
In the HER2CLIMB trial, patients with HER2+ metastatic breast cancer, who had received at least two prior anti-HER2–directed regimens, reported preservation of overall HR-QoL when tucatinib was added to a trastuzumab and capecitabine regimen. Importantly, this durability of HR-QoL throughout the...
She was definitely shutting that conversation down before it could get started. She’s not wrong--the schedule is indeed the schedule when it comes to Herceptin (trastuzumab) and its biosimilars. There is no information on “de-escalating” treatment by extending the time between doses. Every ...
In an interim analysis of the trial, invasive disease or death occurred in 91 patients in the 743-patient T-DM1 group (12.2%) and 165 patients in the 743-patient trastuzumab group (22.2%). The estimated percentage of patients free of invasive disease at 3 years was 88.3% in the T-DM1 ...
respectively. The HSP90 antagonist NVP-AUY922 potentiated anti-cancer effects of a BCL-2 inhibitor in small cell lung cancer27and demonstrated synergy in combination with trastuzumab in breast cancer28. We believe that it is not a coincidence that so many studies currently investigate combination th...
“In this study, we found that the adverse impact of a second cancer on survival was most pronounced in children and AYAs compared with older adults.” The researchers saw significant differences in survival among the common cancer types. For instance, AYA patients diagnosed with AML as...
People withdepressionor anxiety would be better off talking to their doctor about taking an approved prescription medication, Wetter said. "People will tend to say I would rather use something that is natural and organic versus something synthetic, like Prozac or an SSRI," Wetter said. "It is...
Each sample was plated in triplicate, and one control set of wells contained both effector and target cells but no antibody. 2B1, trastuzumab, and the bispecific scFv molecule ML3.9-Y3 were also tested in each cytotoxicity experiment. The ML3.9-Y3 (scFv)2 molecule is similar to the minibody...
Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate, with a topoisomerase I inhibitor payload. Pre-clinical studies have demonstrated that the released payload of T-DXd, unlike T-DM1, is cell-membrane-permeable...